Home Overview Press Room Blog Publications For Students about us
Search

Medical Gene Transfer : Displaying 86-95 of 327


The Battle Over CRISPR Could Make Or Break Some Biotech Companies[cites CGS' Marcy Darnovsky]by Farai ChideyaFiveThirtyEightJanuary 25th, 2016CRISPR is caught up in public offerings and a patent dispute. If used to "edit" heritable traits, it could lead us into a world of genetic haves and have-nots.
Why Morphological Freedom Is a Fantasy: Your Body Isn't Just Your Own[cites CGS]by Sarah SloatInverseJanuary 21st, 2016Transhumanists claim complete freedom to modify their bodies, but that absolutist stance could endanger future generations.
Creativity Week: Playing God with CRISPR[cites CGS' Elliot Hosman]by Aubrey SandersBreakThru RadioJanuary 16th, 2016Elliot Hosman discusses one of the most profoundly consequential debates modern science has ever faced.
CRISPR Patent War: Billions at Stake for UC Berkeleyby Lindsey HoshawKQEDJanuary 15th, 2016Whoever gets the patent will set the terms for how the technology is used.
Why Is Editas Going Public? by Pete ShanksBiopolitical TimesJanuary 14th, 2016Editas, the gene-editing company founded by several of the scientists who developed CRISPR technology, announced on January 4th that it had filed preliminary paperwork for a public offering of stock.
Are we one step closer to designer babies? Genetically-modified embryos could be made in British labs 'within months' if approved tomorrow by Fiona MacRaeThe Daily Mail [UK]January 13th, 2016A researcher has asked for permission to study how manipulating an embryo’s genes would affect the first week of its development.
False Inevitabilities and Irrational Exuberanceby Gina Maranto, Biopolitical Times guest contributorJanuary 8th, 2016In the aftermath on December’s gene editing summit, disquieting themes have emerged in some mainstream media and science blogs.
Who is Smart Enough to Decide how to Improve the Human Species?by Joel AchenbachThe Washington PostJanuary 5th, 2016Genetic engineering and molecular biology benefit from the digital revolution. This convergence is arguably one of the biggest stories in the world right now.
King for a Day? On What’s Wrong With Changing the World for the Better by Roland NadlerLaw and Biosciences BlogJanuary 4th, 2016"It’s not so much about ethics (as we usually envision it) as about political philosophy. I’d exhort us to be quicker to ask: who died and made you king?"
Historic CRISPR Patent Fight Primed To Become Head-To-Head Battleby Alex LashXconomyJanuary 4th, 2016A USPTO patent examiner recommends kicking Jennifer Doudna's application upstairs. The case will be decided under the old "first to invent" standard.
Displaying 86-95 of 327  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760